JPH0214331B2 - - Google Patents
Info
- Publication number
- JPH0214331B2 JPH0214331B2 JP57150733A JP15073382A JPH0214331B2 JP H0214331 B2 JPH0214331 B2 JP H0214331B2 JP 57150733 A JP57150733 A JP 57150733A JP 15073382 A JP15073382 A JP 15073382A JP H0214331 B2 JPH0214331 B2 JP H0214331B2
- Authority
- JP
- Japan
- Prior art keywords
- nisin
- mice
- group
- administered
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 claims description 28
- 108010053775 Nisin Proteins 0.000 claims description 28
- 239000004309 nisin Substances 0.000 claims description 28
- 235000010297 nisin Nutrition 0.000 claims description 28
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 206010003445 Ascites Diseases 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000194035 Lactococcus lactis Species 0.000 description 3
- 235000014897 Streptococcus lactis Nutrition 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- PAWSVPVNIXFKOS-UHFFFAOYSA-N 2-aminobut-2-enoic acid zwitterion Chemical compound CC=C([NH3+])C([O-])=O PAWSVPVNIXFKOS-UHFFFAOYSA-N 0.000 description 1
- UQBOJOOOTLPNST-UHFFFAOYSA-N Dehydroalanine Chemical compound NC(=C)C(O)=O UQBOJOOOTLPNST-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- SJWFXCIHNDVPSH-UHFFFAOYSA-N octan-2-ol Chemical compound CCCCCCC(C)O SJWFXCIHNDVPSH-UHFFFAOYSA-N 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57150733A JPS5942322A (ja) | 1982-09-01 | 1982-09-01 | 制癌剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57150733A JPS5942322A (ja) | 1982-09-01 | 1982-09-01 | 制癌剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5942322A JPS5942322A (ja) | 1984-03-08 |
| JPH0214331B2 true JPH0214331B2 (de) | 1990-04-06 |
Family
ID=15503220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57150733A Granted JPS5942322A (ja) | 1982-09-01 | 1982-09-01 | 制癌剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5942322A (de) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0442630U (de) * | 1990-08-10 | 1992-04-10 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7378386B2 (en) * | 2002-07-15 | 2008-05-27 | Board Of Regents, The University Of Texas System | Anti-viral treatment methods using phosphatidylethanolamine-binding peptide derivatives |
| CA2491310C (en) * | 2002-07-15 | 2015-10-06 | Board Of Regents, The University Of Texas System | Compositions comprising cell-impermeant duramycin derivatives |
| CA2485178A1 (en) * | 2004-11-22 | 2006-05-22 | Universite Du Quebec A Chicoutimi | Lactic acid bacteria-derived bacteriocin and uses thereof for prevention or treatment of cancer |
-
1982
- 1982-09-01 JP JP57150733A patent/JPS5942322A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0442630U (de) * | 1990-08-10 | 1992-04-10 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5942322A (ja) | 1984-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10919935B2 (en) | Antimicrobial peptide derived from myxinidin peptide and uses thereof | |
| JP2009535328A5 (de) | ||
| EP0774255B1 (de) | Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen | |
| EP0235151B1 (de) | Proglumid und dessen pharmazeutische zusammensetzungen zur anwendung bei der behandlung von neoplastischen affektionen | |
| US11766465B2 (en) | External composition for wound healing containing lactobacillus fermentation product and method for promoting wound healing using the same | |
| EP0477050B1 (de) | LPS-produzierende Bakterien, Lipopolysiccharide und LPS enthaltende Arzneimittel und tierärztliche Medikamente | |
| JPH0214331B2 (de) | ||
| US5157106A (en) | N-terminal deletions of lymphotoxin, their preparation and use | |
| CA2516458C (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| CN114404598B (zh) | 脆弱拟杆菌荚膜多糖a联合pd-1抑制剂在制备治疗皮肤肿瘤的药物中的应用 | |
| DE69212267T2 (de) | Echinocandin-B-Derivat | |
| US3634407A (en) | Heavy metal complexes of trihydroxamic acids | |
| KR102039400B1 (ko) | mBjAMP1 펩타이드로부터 유래한 신규 항균 펩타이드 및 이의 용도 | |
| KR101998106B1 (ko) | Hp1404 펩타이드로부터 유래한 신규 항균 펩타이드 및 이의 용도 | |
| Yotis | In vivo and in vitro action of norethindrone on staphylococci | |
| KR101980897B1 (ko) | Ll37 펩타이드로부터 유래한 신규 항균 펩타이드 및 이의 용도 | |
| Carpenter et al. | Chemotherapy of murine leprosy | |
| CN114984004B (zh) | 硫酸舒欣啶在制备抗脓毒症药物中的应用 | |
| EP0369503B1 (de) | Methode zur Kontrolle von Pneumocystis carinii | |
| JPH07126172A (ja) | Ｌｐｓを含む抗ｍｒｓａ剤及び動物用抗ｍｒｓａ剤 | |
| RU2211035C1 (ru) | Противотуберкулезный препарат | |
| Boyd et al. | Isoniazid | |
| US20090104249A1 (en) | Exotoxin Inhibitory Factor | |
| CA1049942A (en) | Enzyme-hormone complex from small intestine | |
| JPH07289273A (ja) | ナフトキノン誘導体 |